CMMB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CMMB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Chemomab Therapeutics's retained earnings for the quarter that ended in Dec. 2024 was $-102.62 Mil.
Chemomab Therapeutics's quarterly retained earnings declined from Jun. 2024 ($-96.18 Mil) to Sep. 2024 ($-99.66 Mil) and declined from Sep. 2024 ($-99.66 Mil) to Dec. 2024 ($-102.62 Mil).
Chemomab Therapeutics's annual retained earnings declined from Dec. 2022 ($-63.82 Mil) to Dec. 2023 ($-88.68 Mil) and declined from Dec. 2023 ($-88.68 Mil) to Dec. 2024 ($-102.62 Mil).
The historical data trend for Chemomab Therapeutics's Retained Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemomab Therapeutics Annual Data | |||||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | ||||||
Retained Earnings | -23.70 | -36.17 | -63.82 | -88.68 | -102.62 |
Chemomab Therapeutics Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Retained Earnings | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-88.68 | -92.55 | -96.18 | -99.66 | -102.62 |
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
Chemomab Therapeutics (NAS:CMMB) Retained Earnings Explanation
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
Orbimed Israel Biofund Gp Limited Partnership | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629 |
George Adi Mor | director, 10 percent owner, officer: Chief Executive Officer | 15 KAFRISIN ST., TEL AVIV L3 6901658 |
Neil Harris Cohen | director | C/O ANCHIANO THERAPEUTICS LTD., ONE KENDALL SQ., BLDG 1400E, STE 14-105, CAMBRIDGE MA 02139 |
Matthew Bejosa Frankel | officer: Chief Medical Officer | 672 PROSPECT AVE., PRINCETON NJ 08540 |
Jill M. Quigley | director | TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103 |
Joel Michael Maryles | director | 5 ATZMON ST., HASHMONAIM L3 7312700 |
Donald Marvin | officer: Executive VP, CFO & COO | 2094 LOST CANYON RANCH CT, CASTLE ROCK CO 80104 |
Dale R Pfost | director, officer: Chief Executive Officer | ACUITY PHARMACEUTICALS INC, 3701 MARKET STREET, PHILADELPHIA PA 19104 |
Nissim Darvish | director | C/O INNOVATE BIOPHARMACEUTICALS, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615 |
Peter Thiel | 10 percent owner | 9200 SUNSET BOULEVARD, SUITE 1110, WEST HOLLYWOOD CA 90069 |
Sigal Fatal | officer: Chief Financial Officer | 16 KANFEY NESHARIM ST., RAMAT GAN L3 5235716 |
Arnon Aharon | officer: Chief Medical Officer | 12 YAVNE ST., TEL AVIV L3 6579116 |
Alan Charles Moses | director | C/O 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002 |
Stephen P Squinto | director | C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410 |
Orbimed Israel Gp Ltd. | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629 |
From GuruFocus
By GuruFocus Research • 03-01-2024
By Marketwired • 04-24-2024
By Marketwired • 06-18-2024
By GuruFocus Research • 03-01-2024
By PRNewswire • 03-05-2024
By Marketwired • 08-21-2024
By PRNewswire • 02-20-2024
By Marketwired • 12-03-2024
By PRNewswire • 03-07-2024
By Marketwired • 08-12-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.